An Avidin-Biotin Conjugation Technique for Presenting Target Antigens on Mycobacterium bovis BCG
JoVE Encyclopedia of Experiments
Immunology
0 views • 3:12 min • July 8th, 2025
Loading...
Overview
This article describes a method for biotinylating Mycobacterium bovis BCG to enhance its immune response properties. The process involves treating the bacteria with a biotinylation reagent and subsequently modifying the surface with avidin-fusion proteins.
Key Study Components
Area of Science
- Microbiology
- Immunology
- Biotechnology
Background
- Mycobacterium bovis BCG is a live vaccine used for tuberculosis.
- Biotinylation allows for the labeling of bacterial surface proteins.
- Avidin-fusion proteins can enhance the immune response.
- Safety precautions are necessary when handling BCG due to its classification as a level II pathogen.
Purpose of Study
- To develop a method for biotinylating BCG cells.
- To facilitate the binding of target antigens to the bacterial surface.
- To enhance the immunogenic properties of BCG.
Methods Used
- Preparation of bacterial suspension with a non-ionic surfactant.
- Incubation with a biotinylation reagent.
- Centrifugation to remove unreacted reagents.
- Modification of bacteria with avidin-fusion proteins.
Main Results
- Successful biotinylation of BCG cells was achieved.
- Avidin-fusion proteins were effectively bound to the bacterial surface.
- The antigen-coated bacteria showed potential for enhanced immune responses.
- Safety protocols were followed during the experiment.
Conclusions
- The biotinylation method can be used to modify BCG for research and therapeutic purposes.
- This approach may improve the efficacy of BCG as a vaccine.
- Further studies are needed to evaluate the immune response triggered by the modified bacteria.
Frequently Asked Questions
What is Mycobacterium bovis BCG?
Mycobacterium bovis BCG is a live attenuated strain of Mycobacterium bovis used primarily as a vaccine against tuberculosis.
Why is biotinylation important?
Biotinylation is important as it allows for the labeling of proteins, facilitating their detection and interaction with other molecules.
What safety precautions are necessary when working with BCG?
It is essential to work in a biosafety cabinet and use personal protective equipment due to BCG being classified as a level II pathogen.
How does avidin-fusion protein enhance immune responses?
Avidin-fusion proteins bind to biotin on the bacterial surface, allowing for the presentation of target antigens to the immune system, potentially enhancing the immune response.
What are the steps involved in the biotinylation process?
The process involves growing the bacteria, treating them with a biotinylation reagent, washing to remove unreacted reagents, and then modifying with avidin-fusion proteins.
Executive Industry Relevance
This avidin-biotin conjugation technique enables non-genetic surface modification of Mycobacterium bovis BCG to present exogenous antigens, offering a strategy to enhance vaccine immunogenicity without altering the bacterial genome. The method supports rapid antigen loading and immune response modulation, relevant for improving prophylactic or therapeutic vaccine candidates. It provides a flexible platform for de-risking antigen presentation approaches in early-stage immunotherapeutic development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of antigen immunogenicity by presenting diverse exogenous targets on a live bacterial vector.
- Operational Value: Provides a reversible, non-genetic system for rapid antigen swapping during target screening.
- Predictive Value: Supports assessment of antigen-specific immune activation in a physiologically relevant microbial context.
Screening & Assay Development
- Scientific Value: Generates standardized antigen-coated bacterial preparations for consistent immune readout assays.
- Operational Value: Facilitates high-throughput testing of antigen variants via modular biotin-avidin coupling.
- Assay Readiness: Produces quantifiable surface-modified bacteria suitable for flow cytometry or ELISA-based antigen presentation tracking.
Translational & Preclinical Research
- Scientific Value: Maintains BCG’s intrinsic immunomodulatory properties while adding defined antigen payloads for mechanistic studies.
- Operational Value: Enables evaluation of antigen dose and presentation kinetics in vivo without genetic engineering timelines.
- Translational Bridge: Supports iterative optimization of antigen candidates prior to committing to genetic vaccine constructs.
Pipeline & Workflow Integration
The technique fits within early discovery workflows where rapid antigen screening and immune profiling are prioritized, particularly for immunomodulatory or infectious disease vaccine candidates.
- Discovery Biology: Supports hypothesis testing of antigen immunogenicity using a clinically relevant bacterial platform.
- Screening: Enables reproducible preparation of antigen-presenting bacteria for comparative immune screening.
- Analytics: Generates measurable outputs such as antigen binding efficiency and immune cell activation levels.
- Translational Research: Connects in vitro antigen presentation to in vivo immune response evaluation in preclinical models.
- Enterprise Reuse: Offers a modular, plug-and-play system adaptable to multiple antigen targets across projects.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence in antigen selection by preserving native BCG immunomodulation.
- Operational Value: Uses standard biotinylation and avidin-binding reagents compatible with existing lab infrastructure.
- Strategic Value: Reduces timeline and cost associated with generating recombinant bacterial strains for each antigen.
- Portfolio Impact: Enables rapid go/no-go decisions on antigen candidates based on immune response data.
Implementation Considerations
- Requires expertise in bacterial culture, biotinylation chemistry, and avidin-fusion protein handling.
- Needs access to biosafety level 2 containment, shakers, centrifuges, and endotoxin-free reagents.
- Demands standardized washing and resuspension protocols to ensure consistent surface modification.
- Must account for potential steric hindrance or orientation effects of fused antigens on immune recognition.
- Limited by the valency and accessibility of surface-exposed biotinylation sites on BCG.
Biopharma FAQs
Why does biotinylation of BCG surface proteins matter for target validation?
Biotinylation labels surface proteins on BCG, enabling controlled attachment of avidin-fusion antigens for consistent presentation in immune assays. This allows researchers to test whether specific antigens can elicit measurable immune responses when displayed on a live bacterial vector. The method supports target validation by linking antigen presentation to immune activation in a reproducible system.
How does isolating the biotinylation step support antigen screening in the discovery pipeline?
Separating biotinylation from avidin-fusion binding allows large batches of biotinylated BCG to be prepared and stored for on-demand antigen loading. This modular approach enables rapid screening of multiple antigens against a standardized bacterial platform. It improves assay consistency and reduces variability in early-stage target evaluation.
What quantitative measurements of antigen binding enable downstream immune assessment?
The amount of avidin-fusion protein bound per bacterium can be estimated using fluorescence-labeled avidin or protein quantification assays after washing. These measurements help correlate antigen density with immune readouts such as cytokine release or T-cell activation. Quantitative binding data supports dose-response modeling in preclinical immune profiling.
Why are replication and washing steps critical for cross-functional collaboration in antigen presentation studies?
Repeated washing removes unbound biotinylation reagents and avidin-fusion proteins, ensuring that only specifically attached antigens contribute to immune signals. This standardization allows different teams to compare antigen-coated BCG preparations with confidence in surface specificity. Consistent protocols reduce false positives and improve data sharing across discovery and preclinical groups.
What analytical capabilities are needed to assess avidin-fusion binding before using antigen-coated BCG in immune studies?
Researchers need methods to quantify biotinylation efficiency and avidin-fusion protein binding, such as spectrophotometric assays, fluorescence detection, or Western blot analysis of bacterial lysates. These capabilities confirm successful surface modification and help optimize reagent concentrations and incubation times. Analytical validation ensures that observed immune responses are due to presented antigens rather than nonspecific binding or reagent artifacts.
10:42
Determining Cell-surface Expression and Endocytic Rate of Proteins in Primary Astrocyte Cultures Using Biotinylation
Related Videos
0 Views
10:43
Bacterial Peptide Display for the Selection of Novel Biotinylating Enzymes
Related Videos
0 Views
12:54
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
Related Videos
0 Views
08:10
A Functional Whole Blood Assay to Measure Viability of Mycobacteria, using Reporter-Gene Tagged BCG or M.Tb (BCG lux/M.Tb lux)
Related Videos
0 Views
03:52
Subcutaneous Injection of Bacterial Antigen to Induce Systemic Inflammation in a Murine Model
Related Videos
0 Views
04:06
Preparation and Quantification of Mycobacterium bovis BCG lux Inoculum for Infection
Related Videos
0 Views
02:59
A Technique to Detect Extrapulmonary Tuberculosis via Superparamagnetic Nanoprobes
Related Videos
0 Views
15:57
Application of Long-term cultured Interferon-γ Enzyme-linked Immunospot Assay for Assessing Effector and Memory T Cell Responses in Cattle
Related Videos
0 Views
12:28
Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments
Related Videos
0 Views
10:11
Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
Related Videos
0 Views
Last updated: 18 July 2026